Share-based Payment Arrangement, Expense of Repare Therapeutics Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Repare Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Repare Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,392,000, a 73% decline year-over-year.
  • Repare Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,324,000, a 50% decline year-over-year.
  • Repare Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $23,160,000, a 7.6% decline from 2023.
  • Repare Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,063,000, a 27% increase from 2022.
  • Repare Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $19,691,000, a 53% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Repare Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,324,000 $1,392,000 -$3,856,000 -73% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $16,180,000 $2,056,000 -$4,463,000 -68% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $20,643,000 $3,958,000 -$2,517,000 -39% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $23,160,000 $4,918,000 -$1,441,000 -23% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $24,601,000 $5,248,000 -$1,129,000 -18% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $25,730,000 $6,519,000 +$254,000 +4.1% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $25,476,000 $6,475,000 +$413,000 +6.8% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $25,063,000 $6,359,000 +$1,221,000 +24% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $23,842,000 $6,377,000 +$1,324,000 +26% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $22,518,000 $6,265,000 +$1,520,000 +32% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $20,998,000 $6,062,000 +$1,307,000 +27% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $19,691,000 $5,138,000 +$1,242,000 +32% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $18,449,000 $5,053,000 +$1,360,000 +37% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $17,089,000 $4,745,000 +$1,562,000 +49% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $15,527,000 $4,755,000 +$2,698,000 +131% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $12,829,000 $3,896,000 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $3,693,000 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $3,183,000 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $2,057,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1

Repare Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $23,160,000 -$1,903,000 -7.6% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $25,063,000 +$5,372,000 +27% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $19,691,000 +$6,862,000 +53% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $12,829,000 +$10,292,000 +406% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $2,537,000 +$2,026,000 +396% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $511,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.